 BRENTWOOD, Tenn, Nov. 05, 2020 GLOBE NEWSWIRE -- IMAC Holdings, Inc. Nasdaq: IMAC IMAC or the Company, a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces it is opening enrollment in its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual slowing and loss of spontaneous body movement, due to Parkinsons disease. 